Linked Life Data

18824067

Source:http://linkedlifedata.com/resource/pubmed/id/18824067

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-3-31
pubmed:abstractText
Prostate cancer is highly prevalent in Western society, and its early stages can be controlled by androgen ablation therapy. However, the cancer eventually regresses to an androgen-independent state for which there is no effective treatment. The renin-angiotensin system (RAS), in particular the octapeptide angiotensin II, is now recognised to have important effects on growth factor signalling and cell growth in addition to its well known actions on blood pressure, fluid homeostasis and electrolyte balance. All components of the RAS have been recently identified in the prostate, consistent with the expression of a local RAS system in this tissue. This review focuses on the role of the RAS in the prostate, and the possibility that this pathway may be a potential therapeutic target for the treatment of prostate cancer and other prostatic diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1872-8057
pubmed:author
pubmed:issnType
Electronic
pubmed:day
29
pubmed:volume
302
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
219-29
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Role of the renin-angiotensin system in prostate cancer.
pubmed:affiliation
University of Melbourne, Department of Medicine, Austin Health, Heidelberg, Victoria, Australia.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't